Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures
- PMID: 12422305
- DOI: 10.1053/sonc.2002.35525
Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures
Abstract
Neurotoxicity is the most frequent dose-limiting toxicity of oxaliplatin. Acute neurotoxicity is characterized by the rapid onset of cold-induced distal dysesthesia and/or paresthesia. Sensory symptoms may also be accompanied by cold-dependent muscular contractions of the extremities or the jaw. The symptoms, often occurring during or shortly after infusion, are usually transient and mild. A persistent sensory peripheral neuropathy may also develop with prolonged treatment, eventually causing superficial and deep sensory loss, sensory ataxia, and functional impairment. Studies have shown patients with acute sensory symptoms to display little or no axonal degeneration, suggesting a specific effect of oxaliplatin on sensory neurons and/or motor neurons or muscle cells that is not observed with other platinum agents. The similarity of the acute symptoms induced by oxaliplatin with those caused by several drugs or toxins acting on neuronal or muscular ion channels suggests that these symptoms may result from a specific interaction of oxaliplatin with ion channels located in the cellular membrane. Recent data indicate that oxaliplatin may act on specific isoforms of the voltage gated sodium (Na(+)) channel to increase the excitability of sensory neurons, an action inhibited by the Na(+) channel blocker carbamazepine. This contention is supported by recent clinical findings indicating that pharmacologic blockade of Na(+) channels may prevent and/or repress the acute neurotoxicity of oxaliplatin. Although there is no indication at the moment that a common cellular mechanism induces both the acute and the cumulative neurotoxicity of oxaliplatin, controlled clinical trials are currently underway to establish the value of Na(+) channel blockade against both acute and cumulative oxaliplatin neurotoxicities.
Copyright 2002, Elsevier Science (USA). All rights reserved.
Similar articles
-
Management of oxaliplatin-induced peripheral neuropathy.Ther Clin Risk Manag. 2005 Dec;1(4):249-58. Ther Clin Risk Manag. 2005. PMID: 18360567 Free PMC article.
-
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10. Brain. 2009. PMID: 19745023
-
[Oxaliplatin neurotoxicity].Bull Cancer. 2006 Feb 1;93 Suppl 1:S17-22. Bull Cancer. 2006. PMID: 16491518 Review. French.
-
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.J Clin Oncol. 2009 Mar 10;27(8):1243-9. doi: 10.1200/JCO.2008.19.3425. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164207
-
Oxaliplatin-related neurotoxicity: how and why?Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68. doi: 10.1016/j.critrevonc.2006.01.001. Epub 2006 Jun 27. Crit Rev Oncol Hematol. 2006. PMID: 16806962 Review.
Cited by
-
Review of systemic therapies for locally advanced and metastatic rectal cancer.J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi: 10.3978/j.issn.2078-6891.2014.112. J Gastrointest Oncol. 2015. PMID: 25830038 Free PMC article. Review.
-
Role of transporters in the distribution of platinum-based drugs.Front Pharmacol. 2015 Apr 24;6:85. doi: 10.3389/fphar.2015.00085. eCollection 2015. Front Pharmacol. 2015. PMID: 25964760 Free PMC article. Review.
-
Impact of oxaliplatin-induced neuropathy: a patient perspective.Support Care Cancer. 2012 Nov;20(11):2959-67. doi: 10.1007/s00520-012-1428-5. Epub 2012 Mar 17. Support Care Cancer. 2012. PMID: 22426503
-
Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016).Int J Nanomedicine. 2014 Jun 19;9:3005-12. doi: 10.2147/IJN.S60564. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24971011 Free PMC article.
-
Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer.Cancer Res Treat. 2004 Apr;36(2):115-20. doi: 10.4143/crt.2004.36.2.115. Epub 2004 Apr 30. Cancer Res Treat. 2004. PMID: 20396550 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical